Welcome to our dedicated page for Arvinas SEC filings (Ticker: ARVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a 300-page biotech filing packed with PROTAC chemistry and clinical trial minutiae is no small task. Arvinas’s SEC documents delve into targeted protein degradation science, collaboration milestones, and cash runway projections—details investors need but rarely have time to extract.
Stock Titan turns that challenge into clarity. Our platform delivers AI-powered summaries that make understanding Arvinas SEC documents with AI effortless. Open the latest Arvinas annual report 10-K simplified to see R&D spend and pipeline timelines distilled in plain English. Need quarterly numbers? The Arvinas quarterly earnings report 10-Q filing is paired with side-by-side trend analysis, while 8-K material events—like pivotal trial readouts—are flagged under “Arvinas 8-K material events explained” so you never miss market-moving news.
Curious about insider confidence? Real-time alerts surface Arvinas Form 4 insider transactions, letting you track Arvinas executive stock transactions Form 4 as soon as they hit EDGAR. You’ll also find a clean view of Arvinas proxy statement executive compensation to benchmark leadership incentives. Whether you’re hunting for Arvinas insider trading Form 4 transactions or a quick Arvinas earnings report filing analysis, our comprehensive coverage—10-K, 10-Q, 8-K, S-8, DEF 14A and more—keeps every document searchable, linked and contextualized. Discover Arvinas SEC filings explained simply and make data-driven decisions faster.
Arvinas, Inc. director Briggs Morrison reported purchasing 30,000 shares of ARVN common stock on 09/22/2025 at a weighted average price of $7.567 per share. After the transaction, Mr. Morrison beneficially owned 76,021 shares. The filing was submitted on 09/24/2025 and signed by an attorney-in-fact.
The footnote clarifies the $7.567 figure is a weighted average for multiple purchases priced between $7.50 and $7.65; the reporting person offered to provide a breakdown of per-trade quantities on request. No derivative transactions or additional securities classes are reported on this Form 4.
Logos Global and affiliated funds report owning a meaningful stake in Arvinas, Inc. The filing shows Logos Global Management and related entities jointly beneficially own 6,300,000 shares, representing 8.6% of Arvinas's outstanding common stock based on 73,417,595 shares. Logos Global Master Fund holds 5,000,000 shares (6.8%) and Logos Opportunities Fund holds 1,300,000 shares (1.8%). Purchases were made on the open market: Global Fund acquired 3,200,000 shares for $23,534,011.75 and exercised 15,000 call options on August 15, 2025 to obtain 1,500,000 shares for $7,500,000; Opportunities Fund acquired 1,300,000 shares for $10,067,317.13. The reporting persons state their purpose is investment but have actively engaged management, recommending a strategic reset including a $700 million return of capital, expense reductions, a 1-for-5 reverse stock split, and refraining from further early-stage pipeline investment absent a strategic partner.
Arvinas announced that the U.S. Food and Drug Administration has accepted the company’s new drug application for vepdegestrant, seeking treatment of patients with estrogen receptor positive (ER+)/HER2-negative disease whose tumors carry ESR1 mutations and who previously received endocrine-based therapy. The filing includes a company press release as Exhibit 99.1.
The FDA has assigned a Prescription Drug User Fee Act action date of June 5, 2026, establishing the target date for the agency’s decision on the application.
Arvinas Director Receives Equity Compensation Package
Director Laurie Smaldone Alsup received significant equity awards from Arvinas (NASDAQ: ARVN) on June 25, 2025. The compensation package includes:
- 16,025 Restricted Stock Units (RSUs) with zero acquisition cost
- 23,105 Stock Options with an exercise price of $7.80 per share and expiration date of June 24, 2035
Both equity awards will vest in full on the earlier of June 25, 2026 or the first board meeting following the next annual stockholder meeting, contingent on continued service. Following these transactions, Smaldone Alsup directly owns 26,045 shares of common stock and 23,105 stock options. This grant appears to be part of the company's regular director compensation program.
FAQ
What is the current stock price of Arvinas (ARVN)?
What is the market cap of Arvinas (ARVN)?
